Research Progress and Application of Lipid-Lowering Drugs and Pharmacogenomics in Managing Chronic Diseases in the Elderly
DOI:
https://doi.org/10.18063/jmds.v10i2.781Keywords:
Elderly, Chronic disease management, Lipid-lowering drugs, PharmacogenomicsAbstract
With the advent of an aging society in China, the elderly population is growing, and their health status and disease burden are also increasing. Cardiovascular and cerebrovascular diseases are the main killers that harm the health of the elderly. Dyslipidemia is one of the independent risk factors for the occurrence of cardiovascular and cerebrovascular diseases. Lipid-lowering drugs, as commonly used drugs to prevent cardiovascular events in clinical practice, are widely used in elderly patients. This article summarizes and categorizes several major types of drugs currently used for lipid-lowering therapy, combining the latest research progress in pharmacogenomics to provide references for lipid-lowering regimens in elderly patients.
References
Lu X, Gao H, Xu X, et al., 2025, Comparative Study on the Current Status of Elderly Health Management Services under the Combination of Medical and Nursing Care in the Community. China Modern Medicine, 32(07): 126–130.
Mo Q, Huang S, Ma J, et al., 2021, Association between SLCO1B1 Polymorphism Distribution Frequency and Blood Lipid Level in Chinese Adults. Br J Biomed Sci, 78(1): 23–27.
Levy Y, Levy D, 2021, A Friend and a Foe: 50 Years of the Apolipoprotein E Research Trail. Isr Med Assoc, 23(10): 665–669.
Fu K, Li Q, Yin D, et al., 2021, Effect of Apolipoprotein E Gene Polymorphism Detection on the Lipid-Lowering Efficacy of ACS Patients. Progress in Modern Biomedicine, 21(06): 1191–1195.
Wang Q, Lin W, 2018, Research Progress of Pharmacogenomics in the Treatment of Cardiovascular Diseases. Chinese Journal of Evidence-Based Cardiovascular Medicine, 10(08): 1012–1014.
Kitzmiller JP, Mikulik EB, Dauki AM, et al., 2016, Pharmacogenomics of Statins: Understanding Susceptibility to Adverse Effects. Pharmgenomics Pers Med, 9: 97–106.
Kameyama Y, Yamashita K, Kobayashi K, et al., 2005, Functional Characterization of SLCO1B1 (OATP-C) Variants, SLC01B15, SLC01B115, and SLCO1B1*15+C1007G, by Using Transient Expression Systems of HeLa and HEK293 Cells. Pharmacogenomics, 15: 513–522.
Qiao Y, Huang JC, Chen YL, et al., 2017, Meat Quality, Fatty Acid Composition, and Sensory Evaluation of Cherry Valley, Spent Layer, and Crossbred Ducks. Animal Science Journal, 88(1): 156–165.
Tian C, Yan Y, Pan Q, et al., 2021, Effects of Jiangzhi 1 on the Expression of NPC1L1 and ABCG5 in the Small Intestine and Caco-2 Cells of Hyperlipidemic Rats. Journal of Cardiopulmonary and Vascular Diseases, 40(10): 1071–1076.
Ding M, Xie L, Yang J, et al., 2025, Effects of Combination Therapy with Ezetimibe Tablets and Atorvastatin Calcium Tablets on Blood Lipid Levels and Neurological Function in Patients with Atherosclerotic Cerebral Infarction. Chinese Medical Innovation, 22(03): 138–142.
Pirillo A, Catapano AL, Norata GD, 2016, Niemann-Pick C1-like 1 (NPC1L1) Inhibition and Cardiovascular Diseases. Curr Med Chem, 23(10): 983–999.
Huang X, Liu X, Wang T, et al., 2017, Clinical Phenotypes and Gene Mutation Analysis of Four Cases of Fatty Acid Hydroxylase-Related Neurodegeneration. Chinese Journal of Modern Nervous Diseases, 17(07): 534–540.
Huang Y, Wang X, Lu J, 2024, Screening and Verification of Targeted Therapeutic Drugs for Metabolically Related Key Differentially Expressed Genes in Non-Alcoholic Steatohepatitis. Shandong Medical Journal, 64(33): 25–29.